An oncologist refers a 58-year-old patient to the gynecology clinic after she reports a recent episode of dark red vaginal spotting. She underwent breast-conserving surgery and radiation for early-stage hormone receptor-positive breast cancer three years ago. Since her surgery, she has been maintained on adjuvant tamoxifen therapy. The patient's last menstrual period occurred naturally at age 52. She denies pelvic pain, dysuria, or systemic symptoms. Her body mass index is . Speculum examination demonstrates pale, thinned vaginal walls with a small amount of blood in the vaginal vault. The cervix appears grossly normal without lesions. Which of the following is the most appropriate next step in management?
- ATransvaginal ultrasonography
- BDiscontinuation of tamoxifen therapy
- Endometrial biopsyCevap
- DCervical cytology and HPV cotesting
- EReassurance and clinical observation
Cevap
Endometrial biopsy
The correct answer is endometrial biopsy. Any postmenopausal bleeding must be thoroughly investigated to rule out endometrial carcinoma. While transvaginal ultrasonography (TVUS) is often an appropriate initial triage step for the general postmenopausal population, it is contraindicated as a primary tool for patients currently taking tamoxifen. Tamoxifen exerts an estrogenic effect on the endometrium and frequently causes subepithelial stromal hypertrophy. This creates a falsely thickened and cystic appearance on ultrasound, rendering the imaging modality highly unreliable. Therefore, patients on tamoxifen who present with postmenopausal bleeding require direct tissue sampling via endometrial biopsy as the initial diagnostic step.
Adım Adım Çözüm
Anahtar Kavram
In patients taking tamoxifen, postmenopausal bleeding must be initially evaluated with an endometrial biopsy rather than transvaginal ultrasonography due to tamoxifen-induced subepithelial stromal hypertrophy causing false-positive thickened stripes on imaging.